Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ensysce Biosciences (ENSC) Operating Margin (2020 - 2025)

Historic Operating Margin for Ensysce Biosciences (ENSC) over the last 6 years, with Q3 2025 value amounting to 758.68%.

  • Ensysce Biosciences' Operating Margin fell 7775400.0% to 758.68% in Q3 2025 from the same period last year, while for Sep 2025 it was 245.89%, marking a year-over-year decrease of 1031900.0%. This contributed to the annual value of 129.18% for FY2024, which is 3513500.0% up from last year.
  • Per Ensysce Biosciences' latest filing, its Operating Margin stood at 758.68% for Q3 2025, which was down 7775400.0% from 127.64% recorded in Q2 2025.
  • Ensysce Biosciences' Operating Margin's 5-year high stood at 18.86% during Q3 2024, with a 5-year trough of 3400.56% in Q2 2022.
  • For the 5-year period, Ensysce Biosciences' Operating Margin averaged around 719.09%, with its median value being 467.7% (2023).
  • Its Operating Margin has fluctuated over the past 5 years, first plummeted by -33077400bps in 2022, then skyrocketed by 29328600bps in 2023.
  • Over the past 5 years, Ensysce Biosciences' Operating Margin (Quarter) stood at 122.71% in 2021, then crashed by -253bps to 432.57% in 2022, then tumbled by -42bps to 612.72% in 2023, then skyrocketed by 55bps to 274.34% in 2024, then plummeted by -177bps to 758.68% in 2025.
  • Its Operating Margin stands at 758.68% for Q3 2025, versus 127.64% for Q2 2025 and 149.08% for Q1 2025.